CClinicalTrials.gg
CompletedNCT02195726EUROCRIPSUpdated Jul 21, 2014

Efficacy of RIPC to Reduce AKI for Patients Undergoing PCI

A Phase 4 interventional study of Remote ischemic preconditioning and Sham remote ischemic preconditioning in Acute Kidney Injury, sponsored by A.O.U. Città della Salute e della Scienza. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-07-21.

Sponsored by A.O.U. Città della Salute e della Scienza · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
1,110
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of the present study is to determine if remote ischemic preconditioning reduces incidence of acute kidney injury in patients with reduced kidney function undergoing Percutaneous Coronary Intervention.

Read the detailed description

Acute kidney injury negatively impacts on prognosis after PCI, and only hydratation have shown to reduce this complication.

Remote ischemic preconditioning has been demonstrated to reduce periprocedural MI, while impact on aki remains to be assessed

02

Conditions studied

  • Acute Kidney Injury

Browse trials for

03

In context

Acute Kidney Injury

1,596 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's enrollment of 1,110 is above the median of 100 across 763 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

A.O.U. Città della Salute e della Scienza is the lead sponsor of 64 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • undergoing PCI with stenting for all clinical indications
  • carrying (with) a renal clearance less than 60 mL/min/1.73 m2 and more than 30 mL/min/1.73 m2 (evaluated through MDRD); ù
  • younger than 85 years old.

Exclusion criteria

Exclusion Criteria:

  • ST Segment Elevation Myocardial Infarction (STEMI), unstable hemodynamic presentations (cardiogenic shock) or ongoing severe arrhythmias;
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,110 participants (actual)

Study arms

  • Sham comparator
    Sham remote ischemic preconditioning'

    In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline

    Procedure: Sham remote ischemic preconditioning

  • Experimental
    Remote ischemic preconditioning

    In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion. In subjects presenting with BMI \> 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation

    Procedure: Remote ischemic preconditioning

Interventions

  • ProcedureRemote ischemic preconditioning

    four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.

  • ProcedureSham remote ischemic preconditioning

    In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.

06

What researchers measure

Primary outcomes

  1. Incidence of acute kidney injury

    Acute Kidney Injury defined as Acute kidney injury is defined as an increase serum creatinine greater than 0.5 mg/dL, or by a relative increase of at least 25% over the baseline value within a period of 48-hours after contrast medium administration

    Time frame: 24 and 48 hours after PCI

Secondary outcomes

  1. Incidence of periprocedural myocardial infarction

    Time frame: 24 and 48 hours after PCI

07

Study locations

7 sites
  • Institut Cardiovasculaire Paris Sud Hôpital Jacques Cartier
    Paris, France
  • Unità Operativa di Cardiologia Presidio Ospedaliero Misericordia Via Senese 161 58100 Grosseto
    Grosseto, Italy
  • Azienda Ospedaliere Senese Siena
    Siena, Italy
  • Ospedale Maria Vittoria
    Turin, 10016, Italy
  • San Luigi
    Turin, 10016, Italy
  • Città Della Salute e Della Scienza
    Turin, Italy
  • Hospital Clínico San Carlos
    Madrid, Spain
08

References and documents

Publications

  • D'Ascenzo F, Femmino S, Ravera F, Angelini F, Caccioppo A, Franchin L, Grosso A, Comita S, Cavallari C, Penna C, De Ferrari GM, Camussi G, Pagliaro P, Brizzi MF. Extracellular vesicles from patients with Acute Coronary Syndrome impact on ischemia-reperfusion injury. Pharmacol Res. 2021 Aug;170:105715. doi: 10.1016/j.phrs.2021.105715. Epub 2021 Jun 7. PubMed 34111564 ↗
  • Moretti C, Cerrato E, Cavallero E, Lin S, Rossi ML, Picchi A, Sanguineti F, Ugo F, Palazzuoli A, Bertaina M, Presbitero P, Shao-Liang C, Pozzi R, Giammaria M, Limbruno U, Lefevre T, Gasparetto V, Garbo R, Omede P, Sheiban I, Escaned J, Biondi-Zoccai G, Gaita F, Perl L, D'Ascenzo F. The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial. Int J Cardiol. 2018 Apr 15;257:1-6. doi: 10.1016/j.ijcard.2017.12.033. PubMed 29506674 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02195726
Lead sponsor
A.O.U. Città della Salute e della Scienza
Responsible party
Claudio Moretti (Dottor, Head of the Catch Lab, A.O.U. Città della Salute e della Scienza) — Principal investigator
First posted
Jul 21, 2014
Start date
Jan 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 21, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion